Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Edwards Lifesciences while lowering the price target from $82 to $71.
September 13, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Edwards Lifesciences and reduced the price target from $82 to $71, indicating a more cautious outlook.
The reduction in the price target from $82 to $71 by Truist Securities suggests a less optimistic view on Edwards Lifesciences' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100